ANTINEUTROPHIL CYTOPLASM ANTIBODIES IN PATIENTS WITH ACR CRITERIA FOR POLYARTERITIS-NODOSA - HELP FOR SYSTEMIC VASCULITIS CLASSIFICATION

被引:10
作者
BARANGER, TAR [1 ]
AUDRAIN, MAP [1 ]
TESTA, A [1 ]
BESNIER, D [1 ]
GUILLEVIN, L [1 ]
ESNAULT, VLM [1 ]
机构
[1] HOP HOTEL DIEU,INST BIOL,IMMUNOL LAB,F-44035 NANTES,FRANCE
关键词
ANCA; AUTOIMMUNITY; MICROSCOPIC POLYANGIITIS; POLYARTERITIS NODOSA; SYSTEMIC VASCULITIS;
D O I
10.3109/08916939508993337
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The american college of rheumatology (ACR) proposed in 1990 revised clinical criteria for systemic vasculitis classification to define homogeneous group of patients for clinical trials. However, microscopic polyarteritis (MPA) was not clearly identified from polyarteritis nodosa (PAN). Since antineutrophil cytoplasm antibodies (ANCA) are markers of disease activity of small vessel vasculitides including MPA, we tested the clinical significance of ANCA in 24 patients with PAN according to the ACR 1990 criteria. Two of 24 patients had ANCA, as defined by indirect immunofluorescence on normal human neutrophils, antigen-specific ELISA and Western blot analysis. However, they exhibited histologically proven small vessel but not medium vessel vasculitis. Furthermore, they had neither artery microaneurysms nor large organ injury consequent upon large vessel occlusion. Although they satisfied ACR criteria for PAN, they probably were misclassified and should be considered as MPA. We conclude that: (i) ANCA are not found in patients with classical PAN in the absence of MPA features; (ii) caution should be exercised when defining PAN according to the ACR 1990 criteria; (iii) ANCA may help systemic vasculitis classification.
引用
收藏
页码:33 / 37
页数:5
相关论文
共 43 条
[1]  
Medsger T.A., Systemic sclerosis (scleroderma), eosinophilic fascilitis, and calcinosis, Arthritis and Allied Conditions12th, pp. 1253-1292, (1993)
[2]  
Norton W.L., Nardo J.M., Vascular disease in progressive systemic sclerosis (scleroderma), Ann. Intern. Med., 73, pp. 317-324, (1970)
[3]  
LeRoy E.C., Trojanowska M., Smith E.A., The pathogenesis of scleroderma (systemic sclerosis, SSc), Clin. Exp. Rheumatol., 9, pp. 173-177, (1991)
[4]  
Giordano M., Valentini G., Migliaresi S., Picillo U., Vatti M., Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis, J. Rheumatol., 13, pp. 911-916, (1986)
[5]  
Steen V.D., Powell D.L., Medsger T.A., Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis, Arthritis Rheum., 31, pp. 196-203, (1988)
[6]  
Alarcon-Segovia D., Deleze M., Oria C.V., Sanchez-Guerrero J., Gomez-Pacheco L., Cabiedes J., Et al., Antiphospholipid antibodies and antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients, Medicine, 68, pp. 353-365, (1989)
[7]  
Lopez L.R., Santos M.E., Espinoza L.R., La Rosa F.G., Clinical significance of immunoglobulin A versus immunoglobulins G and M anticardiolipin antibodies in patients with systemic lupus erythematosus. Correlation with thrombosis, thrombocytopenia and recurrent abortion, Am. J. Clin. Pathol., 98, pp. 449-454, (1992)
[8]  
Picillo U., Migliaresi S., Marcialis M.R., Longobardo A., La Palombara F., Tirri G., Longitudinal survey of anticardiolipin antibodies in systemic lupus erythematosus. Relationships with clinical manifestations and disease activity in an Italian series, Scand. J. Rheumatol., 21, pp. 271-276, (1992)
[9]  
Carreras L.O., Vermylen J.G., Lupus” anticoagulant and thrombosis: possible role of inhibition of prostacyclin formation, Thromb. Haemost., 48, pp. 38-40, (1982)
[10]  
Tsakiris D.A., Marbet G.A., Makris P.E., Settas L., Duckert F., Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant, Thromb. Haemost., 61, pp. 175-177, (1989)